Open Access
ARTICLE
Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
Shoumiao Li*†, Baozhong Li†, Jiaxiang Wang*, Da Zhang*, Zhiqiang Liu†, Zhizhong Zhang†, Wei Zhang†, Yunjie Wang†, Dongxiao Bai†, Jianyun Guan†, Yong Zhang†
* Department of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China
† Department of Surgery, Anyang Tumor Hospital, Anyang, Henan, P.R. China
Oncology Research 2017, 25(1), 93-97. https://doi.org/10.3727/096504016X14719078133564
Abstract
The identification of reliable predictors of chemotherapy sensitivity and early screening of adenocarcinoma
of gastroesophageal junction (AGEJ) patients who are resistant to chemotherapy has become an important
area of clinical and translational research. We aimed to investigate the predictive value of seven cancerassociated cellular proteins for neoadjuvant chemotherapy in AGEJ patients. Clinical data of 93 patients who
received neoadjuvant chemotherapy for locally advanced AGEJ between June 2010 and December 2014 were
reviewed. All patients were administered the combination regimen of S-1 and oxaliplatin (SOX). Expression
of P-glycoprotein (P-gp), glutathione S-transferase-p (GST-π), topoisomerase II (topo II), multidrug resistance gene-associated protein (MRP), lung resistance-related protein (LRP), Ki-67, and p53 was determined by
immunohistochemistry (IHC) in AGEJ tissues before neoadjuvant chemotherapy. Chemotherapeutic efficacy
was evaluated according to RECIST 1.0 standards and histopathological results, and the relationship between
the expression of the cellular proteins and chemotherapy efficacy was analyzed. The SOX regimen was associated with an overall response rate of 46.2%. The frequency of expression of the seven cancer-associated factors
in the AGEJ tissues was as follows: P-gp, 64.5%; GST-π, 39.8%; topo II, 72.0%; MRP, 33.3%; LRP, 68.8%;
Ki-67, 62.4%; and p53, 40.9%. Expression of Ki-67 (
p = 0.003) and p53 (
p = 0.009) was significantly correlated with chemotherapy sensitivity. Elevated Ki-67 expression and decreased p53 expression predict for SOX
insensitivity in AGEJ, and the cellular expression of these respective proteins may provide a useful reference
for designing individualized chemotherapy regimens for AGEJ patients in the future.
Keywords
Cite This Article
APA Style
Li, S., Li, B., Wang, J., Zhang, D., Liu, Z. et al. (2017). Identification of sensitivity predictors of neoadjuvant chemotherapy for the treatment of adenocarcinoma of gastroesophageal junction. Oncology Research, 25(1), 93-97. https://doi.org/10.3727/096504016X14719078133564
Vancouver Style
Li S, Li B, Wang J, Zhang D, Liu Z, Zhang Z, et al. Identification of sensitivity predictors of neoadjuvant chemotherapy for the treatment of adenocarcinoma of gastroesophageal junction. Oncol Res. 2017;25(1):93-97 https://doi.org/10.3727/096504016X14719078133564
IEEE Style
S. Li et al., "Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction," Oncol. Res., vol. 25, no. 1, pp. 93-97. 2017. https://doi.org/10.3727/096504016X14719078133564